Study Finds TB Preventive Treatment Reduces Deaths in HIV Patients

Tuberculosis (TB) remains the leading cause of death among people living with HIV, accounting for roughly a quarter of all AIDS‑related fatalities in 2024. Health authorities report that the disease continues to claim more lives than any other single illness in this population, despite the fact that TB is both preventable and curable with standard treatment regimens. The persistence of this trend highlights gaps in early diagnosis, treatment initiation, and adherence among people with HIV.

The World Health Organization and national public‑health agencies attribute the high mortality rate to a combination of factors, including late presentation of TB symptoms, limited access to rapid diagnostic tests, and interruptions in antiretroviral therapy that weaken immune defenses. Efforts to integrate TB screening into routine HIV care, expand drug‑susceptibility testing, and strengthen community‑based treatment support are being intensified in high‑burden regions. However, resource constraints and health‑system fragmentation continue to impede widespread implementation of these strategies.

Addressing the TB‑HIV nexus remains a critical priority for global health initiatives. Continued investment in preventive measures such as isoniazid preventive therapy, improved vaccination coverage, and enhanced public‑health infrastructure is essential to reduce the disproportionate toll of TB on people living with HIV and to move toward the broader goal of eliminating TB as a public‑health threat.